FY2029 Earnings Estimate for LPTX Issued By HC Wainwright

Leap Therapeutics, Inc. (NASDAQ:LPTX) – Stock analysts at HC Wainwright issued their FY2029 earnings estimates for Leap Therapeutics in a report issued on Wednesday, January 29th. HC Wainwright analyst S. Ramakanth anticipates that the company will earn ($0.29) per share for the year. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Leap Therapeutics’ current full-year earnings is ($1.84) per share.

Other equities research analysts have also recently issued reports about the company. Baird R W cut Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday. Robert W. Baird downgraded Leap Therapeutics from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $9.00 to $1.25 in a research note on Wednesday.

Leap Therapeutics Stock Performance

LPTX opened at $0.52 on Thursday. The stock has a market cap of $19.90 million, a price-to-earnings ratio of -0.27 and a beta of 0.17. The firm’s fifty day moving average is $2.78 and its 200 day moving average is $2.74. Leap Therapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $4.79.

Institutional Trading of Leap Therapeutics

Hedge funds have recently bought and sold shares of the stock. Key Client Fiduciary Advisors LLC increased its holdings in shares of Leap Therapeutics by 12.2% in the fourth quarter. Key Client Fiduciary Advisors LLC now owns 361,253 shares of the company’s stock worth $1,039,000 after purchasing an additional 39,330 shares during the last quarter. HB Wealth Management LLC grew its holdings in Leap Therapeutics by 103.2% during the 4th quarter. HB Wealth Management LLC now owns 51,500 shares of the company’s stock valued at $150,000 after buying an additional 26,150 shares in the last quarter. Exome Asset Management LLC bought a new stake in Leap Therapeutics in the 3rd quarter worth approximately $264,000. Geode Capital Management LLC raised its holdings in shares of Leap Therapeutics by 18.0% during the 3rd quarter. Geode Capital Management LLC now owns 329,291 shares of the company’s stock worth $847,000 after acquiring an additional 50,194 shares in the last quarter. Finally, HighTower Advisors LLC bought a new position in shares of Leap Therapeutics during the 3rd quarter valued at approximately $65,000. Hedge funds and other institutional investors own 30.46% of the company’s stock.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.